---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-024751"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T02:35:11.185855+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aclaris Therapeutics enters $200M ATM equity facility, terminates prior $150M ATM

## Summary
- New Sales Agreement with SVB Securities and Cantor Fitzgerald for up to $200M in common stock at-the-market.
- Prior $150M ATM terminated; $72.7M net proceeds raised from 4.8M shares under prior agreement.
- Commission of 3% of gross proceeds on sales under new agreement.
- Company not obligated to sell any shares; offering at its sole discretion.

## SEC filing metadata
- accession: 0001104659-23-024751
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000110465923024751/0001104659-23-024751-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000110465923024751/tm237408d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-024751
- JSON: https://secwatch.observer/filing/0001104659-23-024751.json
- Plain text: https://secwatch.observer/filing/0001104659-23-024751.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.